Stereochemistry | RACEMIC |
Molecular Formula | C21H13F3N2O4 |
Molecular Weight | 414.3341 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OC3OC(=O)C4=C3C=CC=C4)=CC=C1
InChI
InChIKey=ANMLJLFWUCQGKZ-UHFFFAOYSA-N
InChI=1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)
Talniflumate, a prodrug of niflumic acid, is a potent analgesic and anti-inflammatory drug that has been used for the treatment of rheumatoid diseases. Talniflumate was synthesized by the esterification of a carboxyl group of niflumic acid with the phthalidyl moiety, and it exerts activity in the body through conversion to niflumic acid. Talniflumate has been studied as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma. However, development of these indications appears to have been discontinued. Talniflumate has been approved and marketed for almost 20 years in Argentina and selected other countries (excluding the United States, Europe, and Japan).
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Human pancreatic cancer cell line (MIA PaCa and BxPC-3) were used for activity evaluation. Cells were were incubated with different concentrations of Talniflumate (50, 100, 150 and 200 mkM), gefitinib and the combination of talniflumate and gefitinib for 24h. Cell viability was determined using the MTT method.